Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
November 3, 2021 6:00 AM EDT$14.7 million in net revenue for the third quarter 2021 (122% increase from second quarter 2021)
Steady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage
Addition of two preclinical assets with potential in rare autoimmune conditions to grow and diversify the pipeline
Conference call to be hosted today at 8:30 a.m. ET
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter ended September 30, 2021. Amounts, unless... More
